NICE considers the patient

February 2009
PharmacoEconomics & Outcomes News;2/21/2009, Issue 572, p3
The article reports on a study by the British National Institute for Health & Clinical Excellence (NICE), investigating how value, to patients, is explored when new health technologies are considered, and new guidance on engaging patients in decision surrounding prescribed medicines. The guidance outlines how healthcare professionals can engage and support patients in decisions about taking prescribed medicines, according to the article.


Related Articles

  • Economic evaluation of healthcare technologies using primary research.  // Evidence Based Nursing;Jul2008, Vol. 11 Issue 3, p67 

    The article discusses the need for British clinicians and policy makers to have a clear understanding of the significance of economic evaluations of health technologies. National clinical guidelines and technology assessments to direct practice are produced by the National Institute of Health...

  • Cautions Regarding the Fitting and Interpretation of Survival Curves: Examples from NICE Single Technology Appraisals of Drugs for Cancer. Connock, Martin; Hyde, Chris; Moore, David // PharmacoEconomics;2011, Vol. 29 Issue 10, p827 

    The UK National Institute for Health and Clinical Excellence (NICE) has used its Single Technology Appraisal (STA) programme to assess several drugs for cancer. Typically, the evidence submitted by the manufacturer comes from one short-term randomized controlled trial (RCT) demonstrating...

  • NICE: alone in Europe but not the world. Gillies, Malcolm B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/21/2009, p429 

    No abstract available.

  • A stated preference binary choice experiment to explore NICE decision making. Tappenden, Paul; Brazier, John; Ratcliffe, Julie; Chilcott, James // PharmacoEconomics;2007, Vol. 25 Issue 8, p685 

    Objective: To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services.Method: A stated preference binary choice experiment was used to...

  • Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia. Kamae, Isao // PharmacoEconomics;2010, Vol. 28 Issue 10, p831 

    Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st...

  • Current Issues.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p3 

    The article reports on the recommendation made by the Citizen's Council to the Great Britain National Institute for Clinical Excellence (NICE), for the institute not to use its standard 3.5% discount rate for costs and benefits in situations where healthcare costs are paid for upfront.

  • THE CONCEPT OF EXCEPTIONALITY: A LEGAL FARCE? Ford, Amy // Medical Law Review;Summer2012, Vol. 20 Issue 3, p304 

    How do we decide which treatments should be offered by the National Health Service (NHS) when we cannot afford to fund them all? In the absence of a positive appraisal by the National Institute for Health and Clinical Excellence (NICE), which mandates the provision of a treatment by the NHS,...

  • Economist says NICE should approve fewer costly drugs. O'Dowd, Adrian // BMJ: British Medical Journal (International Edition);7/7/2007, Vol. 335 Issue 7609, p11 

    The article discusses a recommendation from economist Peter Smith, director of the Centre for Health Economics, at the University of York, that Great Britain's National Institute for Health and Clinical Excellence (NICE) should approve fewer costly drugs. Smith, speaking before a health select...

  • NICE result for Exogen and Watch BP Home A.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p11 

    The article reports that a medical technology guidance supporting the Exogen ultrasound bone healing system and the WatchBP Home A device has been published by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics